## Wenjia Feng

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5420528/publications.pdf

Version: 2024-02-01

9 papers	126	1683934 5 h-index	1872570 6 g-index
papers	Citations	II-IIIQEX	g-muex
10 all docs	10 docs citations	10 times ranked	115 citing authors

#	Article	IF	CITATIONS
1	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. PLoS Medicine, 2021, 18, e1003732.	3.9	38
2	Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. PLoS Medicine, 2021, 18, e1003734.	3.9	35
3	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. JCO Precision Oncology, 2021, 5, 378-388.	1.5	26
4	Cell-Free DNA Alterations in the <i>AR</i> Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer. JCO Precision Oncology, 2020, 4, 680-713.	1.5	20
5	Urinary cell-free DNA analysis for tumor mutation detection in patients with oligometastatic colorectal cancer Journal of Clinical Oncology, 2020, 38, e15545-e15545.	0.8	1
6	Abstract 547: Urine tumor DNA MRD detection and correlation with pathologic complete response in muscle-invasive bladder cancer treated with curative-intent radical cystectomy., 2021,,.		0
7	AR enhancer and locus genomic alterations as cell-free DNA biomarkers of primary resistance to AR-directed treatment of metastatic prostate cancer Journal of Clinical Oncology, 2020, 38, 5529-5529.	0.8	O
8	Liquid biopsy <i> AR</i> /enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients Journal of Clinical Oncology, 2022, 40, 171-171.	0.8	0
9	Integrative analysis of urine cell-free DNA for the detection of residual disease in localized bladder cancer patients Journal of Clinical Oncology, 2022, 40, 559-559.	0.8	O